Biologics and biosimilars

In-depth global knowledge of this rapidly maturing field which straddles numerous therapy areas. For five years, I worked closely with IQVIA’s Biosimilars Center of Excellence to produce regular insight pieces on scientific, clinical, regulatory, financial and political developments in the field and have advised several companies on their biosimilars communication programmes.

I have co-authored two published papers on biosimilars. For the 2017 article A Decade of Biosimilars: Have Expectations Been Met? click here and for the 2019 article Use of Big Data to Aid Patient Recruitment for Clinical Trials Involving Biosimilars and Rare Diseases click here


Click here for a white paper I wrote on the molecular biomarker revolution in lung cancer. Click here for a recent publication on real-world data in oncology I developed on behalf of a panel of European oncologists

Functional urology / incontinence

Click here for two consensus publications on urodynamics I developed on behalf of a multi-disciplinary authorship


Experienced in primary and secondary prevention of atherosclerotic conditions, and the management of heart failure


Extensive work on oral hypoglycaemic options, insulins, blood glucose monitoring advances, management of complications


Closely involved with the UK launch of beta interferon over 20 years ago and the burgeoning of disease-modifying options since then


Significant experience in both asthma and COPD

Mental health

Experience is particularly notable in schizophrenia but also depression in its various forms

Rare diseases

Steadily accumulating experience in rare genetic, autoimmune and autoinflammatory conditions

For areas where my experience is less established, I am generally able to get up to speed quickly with the status quo of clinical practice, unmet needs and key issues.